Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430144 | 0.95 | SIGMAR1 (0.45) | SIGMAR1ACHEBCHEBACE1MALT1 | |
| SCHEMBL12430143 | 0.80 | DRD2 (0.46) | SIGMAR1ACHEBCHEBACE1MALT1 | |
| SCHEMBL12430140 | 0.78 | DRD2 (0.46) | SIGMAR1ACHEBCHEBACE1MALT1 | |
| SCHEMBL1901015 | 0.75 | SIGMAR1 (0.48) | SIGMAR1ACHEBCHEBACE1DRD2 | |
| SCHEMBL3088399 | 0.74 | SIGMAR1 (0.47) | SIGMAR1ACHEBCHEBACE1HTR6 | |
| SCHEMBL3088395 | 0.74 | SIGMAR1 (0.47) | SIGMAR1ACHEBCHEBACE1HTR6 | |
| SCHEMBL3085547 | 0.73 | DRD2 (0.49) | SIGMAR1ACHEBCHEBACE1DRD2 | |
| SCHEMBL3085544 | 0.73 | DRD2 (0.49) | SIGMAR1ACHEBCHEBACE1DRD2 | |
| SCHEMBL29960624 | 0.71 | FUCA1 (0.42) | SIGMAR1DRD2ALDH1A1CHRM2CHRM3 | |
| SCHEMBL29961188 | 0.71 | FUCA1 (0.42) | SIGMAR1DRD2ALDH1A1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981919-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981919-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| EP-1796663-A4 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | BENNANI YOUSSEF L | 2009-03-12 | — | — | US | disclosed |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | BENNANI YOUSSEF L | 2009-03-12 | — | — | US | disclosed |
| US-7423056-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423056-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1796663-A2 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006028961-A2 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | HTR5A, HTR2C, HTR2A | SIGMAR1 194/4885ACHE 1117/4885BCHE 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.